We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's How Tempus AI Demonstrates Improving Operating Leverage
Read MoreHide Full Article
Key Takeaways
Tempus AI's Q2 revenues rose 22% to $382.5M, while adjusted EBITDA improved $13.6M to a positive $8M.
Tempus AI expects its $460M convertible notes offering to cut annual interest expenses by more than $30M.
Tempus AI raised its 2026 revenue outlook to $1.595-$1.605B, maintaining adjusted EBITDA guidance of $65M.
Tempus AI (TEM - Free Report) demonstrates improving operating leverage as revenues scaled in the second quarter of 2026. Second-quarter revenues increased 22% year over year to $382.5 million. Meanwhile, adjusted EBITDA reached $8 million, marking a $13.6 million improvement from a loss of $5.6 million in the year-ago quarter. GAAP net income was $5.6 million and cash used in operating activities narrowed to $7.5 million.
The company ended the quarter with $820.7 million in cash, cash equivalents and marketable securities. It also completed a $460 million offering of 0.0% convertible senior notes due 2032, using part of the proceeds to repay its outstanding loan from Ares Capital. It expects the transaction to reduce annual interest expense by more than $30 million and support its goal of achieving positive free cash flow by year-end 2026.
Against this backdrop, Tempus raised its full-year 2026 revenue guidance to $1.595-$1.605 billion, implying approximately 25% growth, while maintaining adjusted EBITDA guidance of about $65 million.
Additionally, this combination of stronger revenue growth, positive quarterly adjusted EBITDA and lower expected interest costs supports the company’s progress toward positive free cash flow. However, achieving its year-end target remains a key execution milestone.
Peer Update
Inspire Medical (INSP - Free Report) exited the second quarter of 2026 with cash and cash equivalents and short-term investments of $320.7 million compared with $283.8 million at the end of first-quarter 2026. INSP does not have any debt on its balance sheet. Therefore, there appears to be no near-term threat to Inspire Medical’s solvency.
Cumulative net cash provided by operating activities at the end of second-quarter 2026 was $36.1 million compared to the cumulative net cash used in operating activities of $4 million a year ago.
iRhythm Holdings (IRTC - Free Report) exited the second quarter of 2026 with cash and cash equivalents and marketable securities of $591 million compared with $550 million at the end of the first quarter of 2026. IRTC does not have any current-year payable debt. Therefore, there appears to be no near-term threat to iRhythm’s solvency. However, the balance sheet is somewhat leveraged. Total debt of $651 million at the end of second-quarter 2026 has remained unchanged sequentially.
View the Zacks #1 Rank List
Image: Bigstock
Here's How Tempus AI Demonstrates Improving Operating Leverage
Key Takeaways
Tempus AI (TEM - Free Report) demonstrates improving operating leverage as revenues scaled in the second quarter of 2026. Second-quarter revenues increased 22% year over year to $382.5 million. Meanwhile, adjusted EBITDA reached $8 million, marking a $13.6 million improvement from a loss of $5.6 million in the year-ago quarter. GAAP net income was $5.6 million and cash used in operating activities narrowed to $7.5 million.
The company ended the quarter with $820.7 million in cash, cash equivalents and marketable securities. It also completed a $460 million offering of 0.0% convertible senior notes due 2032, using part of the proceeds to repay its outstanding loan from Ares Capital. It expects the transaction to reduce annual interest expense by more than $30 million and support its goal of achieving positive free cash flow by year-end 2026.
Against this backdrop, Tempus raised its full-year 2026 revenue guidance to $1.595-$1.605 billion, implying approximately 25% growth, while maintaining adjusted EBITDA guidance of about $65 million.
Additionally, this combination of stronger revenue growth, positive quarterly adjusted EBITDA and lower expected interest costs supports the company’s progress toward positive free cash flow. However, achieving its year-end target remains a key execution milestone.
Peer Update
Inspire Medical (INSP - Free Report) exited the second quarter of 2026 with cash and cash equivalents and short-term investments of $320.7 million compared with $283.8 million at the end of first-quarter 2026. INSP does not have any debt on its balance sheet. Therefore, there appears to be no near-term threat to Inspire Medical’s solvency.
Cumulative net cash provided by operating activities at the end of second-quarter 2026 was $36.1 million compared to the cumulative net cash used in operating activities of $4 million a year ago.
iRhythm Holdings (IRTC - Free Report) exited the second quarter of 2026 with cash and cash equivalents and marketable securities of $591 million compared with $550 million at the end of the first quarter of 2026. IRTC does not have any current-year payable debt. Therefore, there appears to be no near-term threat to iRhythm’s solvency. However, the balance sheet is somewhat leveraged. Total debt of $651 million at the end of second-quarter 2026 has remained unchanged sequentially.